Mladsi, Deirdre M <br/><br/>
Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.  [electronic resource] 

 -  Current medical research and opinion  Dec 2004 
 - 1883-93 p.  digital 
<br/><br/> Publication Type: Comparative Study; Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0300-7995 
<br/><br/><label>Standard No.: </label>10.1185/030079904X11510  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antipsychotic Agents--economics<br/>Benzodiazepines--economics<br/>Costs and Cost Analysis<br/>Dibenzothiazepines--economics<br/>Drug Costs--statistics & numerical data<br/>Female<br/>Humans<br/>Inpatients<br/>Male<br/>Mental Health Services--statistics & numerical data<br/>Middle Aged<br/>Olanzapine<br/>Quetiapine Fumarate<br/>Retrospective Studies<br/>Risperidone--economics<br/>Schizophrenia--drug therapy